Insulet Announces CFO Transition
PODD(NASDAQ:PODD) ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. “I want to personally thank Ana, who has provided steady and thoughtful leader
Insulet Elevates Eric Benjamin to Chief Operating Officer
PODDACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. In this expanded role, Mr. Benjamin will lead Insulet’s end-to-end growth and innovation engine, setting strategy and guiding
Insulet to Participate in Upcoming Investor Conferences
PODDACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time): Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m. Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m. Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York Ci
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
PODDACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company’s guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, o
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
PODDACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom’s latest diabetes management technology, all conveniently controlled from an iPhone. This integration re
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
PODDGoldman Sachs Initiates Coverage On Insulet with Buy Rating, Announces Price Target of $380
PODDGoldman Sachs Initiates Coverage On Insulet with Buy Rating
PODDHere's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
PODDRaymond James Maintains Outperform on Insulet, Raises Price Target to $360
PODD5 Analysts Assess Insulet: What You Need To Know
PODD$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
PODDWolfe Research Upgrades Insulet to Outperform, Announces $350 Price Target
PODDOppenheimer Maintains Outperform on Insulet, Raises Price Target to $324
PODDInsulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad
PODDInsulet beat Q1 expectations with $569 million in revenue and raised its 2025 outlook as global Omnipod adoption drives double-digit growth.
Insulet Sees Q2 Sales $605.740M-$620.395M vs $577.77M Est
PODDInsulet Raises FY2025 Sales Guidance from $2.40B-$2.49B to $2.49B-$2.55B vs $2.45B Est
PODDInsulet Q1 Adj. EPS $1.02 Beats $0.80 Estimate, Sales $569.00M Beat $543.40M Estimate
PODDThe Analyst Verdict: Insulet In The Eyes Of 7 Experts
PODD7 analysts have shared their evaluations of Insulet (NASDAQ:PODD) during the recent three months, expressing a mix of bullish and bearish perspectives.
Wolfe Research Downgrades Insulet to Peer Perform
PODDInsulet Expects To Exceed Q1 Revenue Growth Outlook Of 22%-25% And Raise FY25 Revenue Growth Outlook From Prior 16%-20%
PODDInsulet Names Ashley McEvoy as New CEO, Replacing Jim Hollingshead in Leadership Shakeup
PODD$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
PODDWhat's Driving the Market Sentiment Around Insulet?
PODDHere's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
PODDInsulet's RADIANT Trial Shows Omnipod 5 Improves Glycemic Control by 0.8% Over Three Months; Achieves +5.4 Hours in Target Glucose Range Daily; Primary Endpoint Met
PODDInsulet Intends To Offer $450M Principal Amount Of Senior Unsecured Notes Due 2033 In A Private Placement
PODDInsulet Makes Omnipod 5 Automated Insulin Delivery (AID) System Available In Australia
PODD$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
PODDRBC Capital Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $340
PODDWhat's Driving the Market Sentiment Around Insulet?
PODD$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
PODDInsulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
PODDInsulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.
Citigroup Maintains Buy on Insulet, Raises Price Target to $355
PODDRaymond James Reiterates Outperform on Insulet, Raises Price Target to $328
PODDStifel Maintains Hold on Insulet, Raises Price Target to $293
PODDPiper Sandler Maintains Overweight on Insulet, Raises Price Target to $310
PODDWells Fargo Maintains Overweight on Insulet, Raises Price Target to $322
PODDAssessing Insulet: Insights From 6 Financial Analysts
PODDCanaccord Genuity Maintains Buy on Insulet, Raises Price Target to $324
PODDInsulet Sees FY25 Revenue Growth 16%-20%
PODDInsulet Q4 2024 Adj EPS $1.15 Beats $1.02 Estimate, Sales $597.50M Beat $582.81M Estimate
PODDInsulet Launches Omnipod 5 In Five More Countries In Italy, Denmark, Finland, Norway And Sweden
PODD9 Analysts Have This To Say About Insulet
PODDBernstein Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $300
PODD